

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation						
1. Given Name (First Name) James		2. Surname (Last Name) Lindsay	3. Effective Date (07-August-2008) 30-September-2016					
4. Are you the cor	responding author?	✓ Yes No						
5. Manuscript Title 2016-2017 ECCO Annual Disclosure of potential conflicts of interest								
6. Manuscript Identifying Number (if you know it)								

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant	✓					×		
						ADD		
2. Consulting fee or honorarium	✓					×		
						ADD		
3. Support for travel to meetings for the study or other purposes	✓					×		
						ADD		
 Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like 	✓					×		
						ADD		
Payment for writing or reviewing the manuscript	✓					×		
						ADD		
Provision of writing assistance, medicines, equipment, or administrative support	✓					×		



The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
						ADD		
7. Other	✓					×		
						ADD		

Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership		✓		Atlantic Health	Advisory Board	×		
1. Board membership		✓		Abbvie UK / Global	Advisory Board	×		
1. Board membership		✓		MSD UK	Advisory Board	×		
1. Board membership		✓		Shire UK	Advisory Board	×		
1. Board membership		✓		Vifor Pharma	Advisory Board	×		
1. Board membership		✓		Ferring international	Advisory Board	×		
1. Board membership		✓		Celltrion	Advisory board	×		
1. Board membership		✓		Takeda	Advisory board	×		
1. Board membership		✓		Napp	Advisory board	×		
1. Board membership		✓		Pfizer	Advisory Board	×		
1. Board membership		√		Janssen	Advisory Board	×		
						ADD		
2. Consultancy		✓		Abbvie UK	development of UC treatment algorhythms	×		

^{*} This means money that your institution received for your efforts on this study.

^{**} Use this section to provide any needed explanation.



Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
2. Consultancy		✓		Takeda	Comments to UK press re vedolizumab	×		
2. Consultancy		✓		Takeda	Development of publication strategy	×		
2. Consultancy		✓		Pfizer	IBD Link	×		
2. Consultancy				Takeda	IBD unmasked	×		
						ADD		
3. Employment	✓					×		
						ADD		
4. Expert testimony	✓					×		
					Investigator lad recearch	ADD		
5. Grants/grants pending			✓	Shire UK	Investigator led research grant	×		
5. Grants/grants pending			\checkmark	Shire UK	NHS Service support grant	×		
5. Grants/grants pending			\checkmark	Abbvie UK	NHS Service support grant	×		
5. Grants/grants pending			\checkmark	Warner Chilcott	NHS service support grant	×		
5. Grants/grants pending			\checkmark	Takeda	Investigator led research grant	×		
5. Grants/grants pending			\checkmark	Hospira	Investigator led research grant	×		
						ADD		
Payment for lectures including service on speakers bureaus		✓		Abbvie UK	lecture fees for UK symposia	×		
Payment for lectures including service on speakers bureaus		✓		Abbvie International	Lecture fees for international symposia	×		
Payment for lectures including service on speakers bureaus		✓		Ferring International	Lecture fees for international symposia	×		
Payment for lectures including service on speakers bureaus		✓		Ferring UK	Lecture fees for UK symposia	×		
Payment for lectures including service on speakers bureaus		✓		MSD UK	Lecture fees for UK symposia	×		
Payment for lectures including service on speakers bureaus		✓		Warner Chilcott	Lecture fees for symposia	×		
Payment for lectures including service on speakers bureaus		✓		Shire UK	Lecture fees for UK symposia	×		



6.	Payment for lectures including service on speakers bureaus		✓	Takeda	International symposia and UK symposia	×
6.	Payment for lectures including service on speakers bureaus		✓	Cornerstones US	Development and delivery of best of DDW lecture series	×
6.	Payment for lectures including service on speakers bureaus		✓	Tillotts	International lecture	×
6.	Payment for lectures including service on speakers bureaus		✓	Napp	Lecture in UK	×
6.	Payment for lectures including service on speakers bureaus		✓	Shire International	Meet the experts / SAGES symposium	×
6.	Payment for lectures including service on speakers bureaus		✓	Janssen	BSG symposia	×
						ADD
7.	Payment for manuscript preparation	✓				×
						ADD
8.	Patents (planned, pending or issued)	✓				×
						ADD
9.	Royalties	√				×
						ADD
10.	Payment for development of educational presentations		✓	Abbvie International	faculty of IBD ahead Faculty of Leading Change Faculty of International Expert Exchange	×
10.	Payment for development of educational presentations		✓	Cornerstones UK	Development of Best of DDW program	×
10.	Payment for development of educational presentations		✓	Shire Global	Development of best of UEGW program	×
10.	Payment for development of educational presentations			Pfizer	Development of IBD link	×
						ADD
11.	Stock/stock options	✓				×
						ADD
12.	Travel/accommodations/ meeting expenses unrelated to activities listed**		✓	Abbvie UK	UEGW 2012 / DDW 2013	×
12.	Travel/accommodations/ meeting expenses unrelated to activities listed**		✓	MSD UK	DDW 2012	×



12. Travel/accommodations/ meeting expenses unrelated to activities listed**		√		MSD UK	ECCO 2012	×			
12. Travel/accommodations/ meeting expenses unrelated to activities listed**		√		Shire UK	UEGW 2011	×			
12. Travel/accommodations/ meeting expenses unrelated to activities listed**		√		Warner Chilcott Uk	DDW 2014 / DDW 2015	×			
 Travel/accommodations/ meeting expenses unrelated to activities listed** 		✓		Takeda	DDW 2016	×			
 Travel/accommodations/ meeting expenses unrelated to activities listed** 		√		Shire	UEGW 2015	×			
						ADD			
13. Other (err on the side of full disclosure)	✓					×			
* This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.									
Section 4. Other relationsh	nips								
Are there other relationships or activi potentially influencing, what you wro	ote in the	submitte	ed work?						
✓ No other relationships/conditions/circumstances that present a potential conflict of interest Yes, the following relationships/conditions/circumstances are present (explain below):									
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.									
Hide All Table Rows Checked 'No' SAVE									

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$